Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
183
-
Total 13F shares, excl. options
-
111M
-
Shares change
-
-14.9M
-
Total reported value, excl. options
-
$160M
-
Value change
-
-$24.3M
-
Put/Call ratio
-
3.94
-
Number of buys
-
76
-
Number of sells
-
-84
-
Price
-
$1.44
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q1 2025
226 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2025.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 183 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 111M shares
of 207M outstanding shares and own 53.63% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (14.5M shares), VANGUARD GROUP INC (11.5M shares), WASATCH ADVISORS LP (10.9M shares), Bellevue Group AG (9.69M shares), Two Seas Capital LP (6.93M shares), MORGAN STANLEY (6.59M shares), STATE STREET CORP (4.55M shares), GEODE CAPITAL MANAGEMENT, LLC (4.45M shares), MARSHALL WACE, LLP (3.63M shares), and Nuveen, LLC (3.09M shares).
This table shows the top 183 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.